BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (March 2016)

27 slides from BioSpecifics Technologies's investor presentation, Mar 14, 2016

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of: & INJECTABLE COLLAGENASE oma _— Cp BioSpecifics March 2016

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995, All statements other than statements of historical fact, including statements regarding

  3. Slide 3: Company Overview

    Company Overview (NASDAQ: BSTC 60060906 Originator of collagenase based-therapies Profitable biopharma company with lean corporate structure and stock buy-back program Receives revenues from XIAFLEX® milestones, royalties on net sales, mark-up. on COGS and sublicense income by partner Endo $8.25M lu

  4. Slide 4: Unlocking Vast Potential of XIAFLEX

    Unlocking Vast Potential of XIAFLEX® XIAFLEX: First-in-class, minimally invasive nonsurgical treatment for conditions caused by collagen accumulation with limited current treatment options BioSpecifics has positive clinical results in 12 indications Drive R&D in new indications to early proof-of-con

  5. Slide 5: Marketed XIAFLEX Indications

    Marketed XIAFLEX Indications: First, Effective Nonsurgical Treatment Options BIOSPECIFICS TECHNOLOGIES CORP. 5

  6. Slide 6: Dupuytren's Contracture

    XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Deforming condition of the hand in which one or more fingers contracts toward the palm Limits range of motion and impairs quality of life Affects between 3-9% of adult Caucasians Pre-treatment: Post-treatment: Source: Endo Internati

  7. Slide 7: Commercial Highlights for Dupuytren's Contracture

    Commercial Highlights for Dupuytren’s Contracture ~8,400 vials shipped in 4Q15 in U.S. ~1.2 vials/patient First commercial sale in Japan in September 2015 Updated U.S. label including recurrence and retreatment data approved in May 2015 E.U. label expansion approved in November 2015, following Octob

  8. Slide 8: Peyronie's Disease

    XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self

  9. Slide 9: Commercial Highlights for Peyronie's Disease

    Commercial Highlights for Peyronie’s Disease ~8,000 vials shipped in 4Q15 in U.S. ~4.5 vials/patient Seeking to expand the market through a new unbranded educational campaign “Ask About the Curve” with Jerry Punch, M.D. and Men's Health Network In May 2015: The American Urological Association presen

  10. Slide 10: Pipeline Indications

    XIAFLEX® Pipeline Indications

  11. Slide 11: Pipeline Programs

    XIAFLEX® Pipeline Programs ture Revenue-Generating Opportunities i 1 Phase 2b recently Cellulite ipecea - Phase 2b to initiate ae nee endo, Pd following 1016 FDA Ga discussion Human Phase 2 top-line Lipoma results in 2016 , Endo has license pone 10 for further Pp development ence => Initiate trial i

  12. Slide 12: Adhesive Capsulitis

    XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia Long-term intensive physical thera

  13. Slide 13: Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis

    Phase 2b Study Results of XIAFLEX® in Adhesive Capsulitis/Frozen Shoulder Syndrome Phase 2a Results th. 321 patient double-blind, placebo-controlled study evaluating safety and efficacy in Stage 2 (frozen stage) unilateral idiopathic frozen shoulder Primary endpoint: change in degrees from baseline

  14. Slide 14: Cellulite: Phase 2b Study Initiated

    XIAFLEX® for Cellulite Phase 2b Study Initiated in February 2016 Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Affects ~85-98% of post-pubertal females Phase 2b Study Design Enrolling 350 women (18+ years) Up to 3 treatment sessions

  15. Slide 15: Cellulite: Positive Top-line Data from Phase 2a

    XIAFLEX® for Cellulite Positive Top-line Data from Phase 2a Study Top-line data from Phase 2a study: 150 women received up to three treatment sessions of drug or placebo according to randomization (5 high-dose (0.84mg): 5 mid (0.48mg): 5 low (0.06mg): 3 placebo) Mid and high level XIAFLEX® doses dem

  16. Slide 16: Human Lipomas

    XIAFLEX® for Human Lipomas Phase 2 Opt-In Study Managed by BioSpecifics Encapsulated deposits of benign fatty tumors; detected as bulges under the skin Potential to be Only FDA Approved No FDA-approved pharmaceutical therapies available Nonsurgical Surgery not practical for patients with multiple li

  17. Slide 17: Positive Phase Clinical Trial Results

    Positive Phase 2 Clinical Trial Results Open label, dose escalation Phase 2 trial Statistically significant (p<0.0001) reduction in primary endpoint of surface area of lipoma as measured by caliper, combining all patients Patients in highest dose group (75% of commercial dose) achieved best efficacy

  18. Slide 18: Lipomas in Canines

    XIAFLEX® for Lipomas in Canines Potential to be Only FDA Approved Nonsurgical Therapy Key Complications Market Opportunity Chien-804 Trial Results Lipomas can seriously restrict motion in older dogs Surgery can be risky due to the use of general anesthesia - especially for older dogs 1.7M dogs affec

  19. Slide 19: Uterine Fibroids

    XIAFLEX® for Uterine Fibroids Clinical Trial to Begin in 2H16 Following Positive FDA Meeting in Late 2015 Benign tumors in the reproductive tract that contain large amounts of collagen Definition & Key Cause pelvic discomfort and pain, decreased fertility, pregnanc Complications foe anes Balt, ility

  20. Slide 20: Lateral Hip Fat

    XIAFLEX® for Lateral Hip Fat Early Opt-In by Partner Endo Definition & Complications Similar prevalence to cellulite Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and a

  21. Slide 21: Plantar Fibromatosis

    XIAFLEX® for Plantar Fibromatosis Early Opt-In by Partner Endo Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, P

  22. Slide 22: Additional Promising Indications

    Additional Promising Indications Capsular Contracture, Breast ~15% of breast augmentation / reconstructive surgery patients Hypertrophic Scars & Keloids ~600,000 scar and “400,000 keloid patients Dercum’s Disease Extremely rare condition Knee Arthrofibrosis ~100,000 patients per year in U.S. Urethra

  23. Slide 23: Endo Partnership for Development and Commercialization of XIAFLEX

    Endo Partnership for Development and Commercialization of XIAFLEX® >$75.8M Received as of Dec. 31, 2015 Future Payments Due to BioSpecifics from Endo Endo Opt-In Rights Sublicense Income from Endo Partnerships $75.8M received in licensing, sublicensing, milestone, COGS, and royalty payments as of De

  24. Slide 24: Strong IP Portfolio

    Strong IP Portfolio Long-term patent protection for XIAFLEX® Dupuytren’s Contracture Drug product composition patent until 2028 Biologic Exclusivity until 2022 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Patents and Patent Applications Owne

  25. Slide 25: Consistently Profitable Annually

    Consistently Profitable Annually Financial Highlights (unaudited) For the quarter ended For the year ended 12/31/15 12/31/14 12/31/15 12/31/14 Cash and equivalents, and investments $37,081,957 $21,961,252 Income Statement Revenues $6,138,867 $4,647,648 $22,750,135 $14,044,624 Other income 42,589 12,

  26. Slide 26: Anticipated Upcoming Pipeline Milestones

    Anticipated Upcoming Pipeline Milestones C1 Phase 2 placebo-controlled opt-in trial top-line i * Burman tipomas results in 2Q16 C1 Initiate clinical trial in 2H16 following FDA meeting in Uterine Fibroids late 2015 Adhesive Capsulitis C1 Initiate Phase 2b trial following 1Q16 FDA discussion U1 Annou

  27. Slide 27: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercialization of & INJECTABLE COLLAGENASE ge ny . BioSpecifics March 2016

Biospecifics Technologies — Investor Presentation (March 2016) on 6ix